1 Alter MJ. Epidemiology of hepatitis B in Europe and worldwide[J]. J Hepatol, 2003, 39(Suppl 1): S64-S69.
[2]
2 Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus[J]. J Clin Gastroenterol, 2004, 38(10, S): S158-S168.
[3]
3 Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures[J]. J Viral Hepat, 2004, 11(2): 97-107.
[4]
5 Liang X, Bi S, Yang W, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China[J]. J Infect Dis, 2009, 200(1): 39-47.
[5]
6 Lu FM, Zhuang H. Management of hepatitis B in China[J]. Chin Med J (Engl), 2009, 122(1): 3-4.
[6]
7 Lee WM. Hepatitis B virus infection[J]. N Engl J Med, 1997, 337(24): 1733-1745.
[7]
8 Liu C, Wang YM, Fan K. Epidemiological and clinical features of hepatitis B virus related liver failure in China[J]. World J Gastroenterol, 2011, 17(25): 3054-3059.
[8]
9 Tan YJ. Hepatitis B virus infection and the risk of hepatocellular carcinoma[J]. World J Gastroenterol, 2011, 17(44): 4853-4857.
[9]
10 Moskovitz DN, Osiowy C, Giles E, et al. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance[J]. J Viral Hepat, 2005, 12(4): 398-404.
[10]
11 Yldz O, Aygen B, Demirtürk N, et al. Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D[J]. World J Gastroenterol, 2011, 17(45): 4987-4992.
[11]
12 Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers[J]. J Hepatol, 2001, 34(4): 584-586.
[12]
13 Ming XC, Miao XH, Zhao SM, et al. The spontaneous YMDD mutation rate in chronic hepatitis B patient[J]. Chin J Hepatol, 2009, 17(12): 887-890.
[13]
14 Shin YM, Heo J, Kim GH, et al. Natural YMDD motif mutations of HBV polymerase in the chronic hepatitis B virus infected patients[J]. Taehan Kan Hakhoe Chi, 2003, 9(1): 1-9.
[14]
15 Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma[J]. Gut, 2004, 53(10): 1494-1498.
[15]
16 Kao JH, Chen PJ, Lai MY, et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B[J]. Gastroenterology, 2000, 118(3): 554-559.
[16]
17 Orito E, Ichida T, Sakugawa H, et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan[J]. Hepatology, 2001, 34(3): 590-594.
[17]
18 Wong GL, Chan HL, Yiu KK, et al. Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2013, 37(5): 517-526.
21 Hosaka T, Suzuki F, Kobayashi M, et al. Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants[J]. Hepatol Res, 2010, 40(2): 145-152.
[21]
22 Ohkubo K, Kato Y, Ichikawa T, et al. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma[J]. Cancer, 2002, 94(10): 2663-2668.
[22]
4 Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine, 2009, 27(47): 6550-6557.
